CEL-SCI (AMEX:CVM) has potential upside of 859.7% based on a current price of $0.73 and analysts' consensus price target of $7.00. The stock should find initial resistance at its 50-day moving average (MA) of $0.74 and further resistance at its 200-day MA of $1.77.
In the past 52 weeks, CEL-SCI share prices have been bracketed by a low of $0.53 and a high of $3.90 and are now at $0.73, 38% above that low price. The 200-day and 50-day moving averages have moved 2.35% lower and 2.01% lower over the past week, respectively.
CEL-SCI Corporation researches and develops certain drugs and vaccines. The Company's Multikine is being tested to determine if it is effective in improving the immune response of cancer patients. CEL-SCI is also developing other products. The Company is currently targeting diseases such as AIDS, herpes simplex, malaria, tuberculosis, prostate cancer, and breast cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.